NEW WCN19 website banner greybg wdates

wcn 2017 logo

WCN2017AbstractBanner

wcn2017 webbanner 1200x168

Late breaking clinical trials
15/04/2019 at 8:30 - 10:10

Join the Late breaking clinical trials session at the ISN World Congress of Nephrology (WCN) 2019. This unique session will feature the first-ever presentation of results from major kidney trials that will change daily clinical practice.

CREDENCE clinical trial

WCN 2019 is proud to announce that the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Clinical Trial early results will be disclosed during the Late breaking clinical trials session on Monday 15 April, 2019.

The CREDENCE trial, a comparative study of the efficacy and safety of canagliflozin versus placebo, has been concluded on the basis of a planned interim data analysis. CREDENCE was a randomized, double-blind, placebo controlled study involving multiple clinical centers. It enrolled about 4400 patients with T2D, with estimated glomerular filtration rate (eFGR) ≥30 to <90 mL/min/1.73 m2, and albuminuria.

The trial steering committee announced an early end to a phase 3 of canagliflozin (Invokana) for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), due to its achieving pre-specified efficacy criteria. Could this be the first therapy to prevent kidney failure in people with type 2 diabetes and chronic kidney disease in over 15 years?

This session will be a unique opportunity for understanding the trial, its results and importance to patients.

More late breaking clinical studies will be presented in the same session on April 15, 2019, including the first results from the SONAR trial of atrasentan vs placebo, and the long-term follow up data from the ACTIVE dialysis trial.